Project: Projeto n. 519 - COVID-19 - Fase 2

Project name:	COVID-19 - Fase 2 - Projeto n.519, Unresolved inflammation and endothelitis in severe COVID-19 patients: identification of risk stratification biomarkers and therapeutic targets.
Project code:	Projeto n. 519 - COVID-19 - Fase 2
Proposing institution/Lead promoter/Coordinating entity:	Faculdade de Medicina da Universidade do Porto
Partner(s)/Co-promoter(s)/Participating institution(s):	Unidade Local de Saúde São João
Start date:	2020-07-09
Completion date:	2021-07-31

Eligible Cost of the Project

Total Eligible Cost:	40.000,00 EUR
Eligible Cost in the University of Porto:	40.000,00 EUR
Faculdade de Medicina da Universidade do Porto:	40.000,00 EUR

Total Financial Support

Orçamento de Estado:

40.000,00 EUR

Financial Support to the University of Porto

Total of the University of Porto:	40.000,00 EUR
Nacional/Regional \| Orçamento de Estado \| Faculdade de Medicina da Universidade do Porto:	40.000,00 EUR

Objectives, activities and expected/achieved results

Objetivos:

To assess, compare and correlate:
1) the systemic inflammatory and proresolving profiles;
2) endothelial activation/dysfunction and coagulation status;
3) oxidative stress/oxidative damage;
4) RAAS activity
in ICU COVID-19 patients, non-ICU COVID-19 patients and healthy
controls, to identify risk stratification biomarkers and putative therapeutic
targets to prevent and counteract the development of cytokine storm and
multiorgan damage caused by COVID-19.

Resultados esperados:

1) Impaired resolution of inflammation (reduced values of SPMs),
enhanced endothelial activation and coagulation, augmented oxidative
damage and marked RAAS activation in severe COVID-19 patients.
2) Demonstration of endocan usefulness as a tool for the prediction of
ARDS development, severity and mortality in COVID-19 patients.

Recommend this page Top

Copyright 1996-2025 © Faculdade de Farmácia da Universidade do Porto I Terms and Conditions I Acessibility I Index A-Z I Guest Book
Page created on: 2025-06-16 at 10:50:53 | Acceptable Use Policy | Data Protection Policy | Complaint Portal